CN1927260A - Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis - Google Patents
Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN1927260A CN1927260A CN 200610110552 CN200610110552A CN1927260A CN 1927260 A CN1927260 A CN 1927260A CN 200610110552 CN200610110552 CN 200610110552 CN 200610110552 A CN200610110552 A CN 200610110552A CN 1927260 A CN1927260 A CN 1927260A
- Authority
- CN
- China
- Prior art keywords
- oil
- walnut oil
- bone
- osteoporosis
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation for the prevention and treatment of osteoporosis, wherein the preparation is made from walnut oil, and can be made into dose forms including tablets, capsules, granules, electuaries, oral liquids, externally preparations, injections and any clinically applicable pharmaceutical preparations.
Description
Technical field the present invention relates to walnut oil is used for the pharmaceutical preparation of protect against osteoporosis and skin aging and health and beauty in preparation application.
Background technology health and longevity are the life sciences Eternal Theme.Along with the acceleration aging of world population, research on anti-senescence has become an applied science of rapid emergence.The position the earliest of human senility is osseous tissue and skin.Medical research proves: the aging of people's bone after 20 years old has just slowly begun, and after 50 years old, osteoporosis is accelerated greatly, and causes fracture easily.Osteoporosis makes one of old and feeble important symbol, and another is exactly a skin aging, and skin aging is the part of organism aging process, and wearing out of body shows the clearlyest on skin.Protect against osteoporosis and skin aging have become the focus of medical scientific, but few people connect the two.We are in the research process of defying age and osteoporosis, find that several plant oils has the osteoporotic effect of good preventing, the function of excellent prevention skin aging is also arranged simultaneously, and this several plant oils is walnut oil, Radix Oenotherae erythrosepalae oil, Fructus Perillae oil, wheat germ oil, safflower oil.
This project of summary of the invention seminar finds the effect that several plant oils walnut oil, wheat germ oil, Radix Oenotherae erythrosepalae oil, Fructus Perillae oil, safflower oil have protect against osteoporosis, simultaneously, the effect that has the prevention skin aging again, can be used for preparing the pharmaceutical preparation of protect against osteoporosis, also can be used for preparing the preparation that prevents skin aging.
Above-mentioned vegetable oil can be made into tablet, capsule, granule, electuary, oral liquid, external preparation, injection and any for clinical practice pharmaceutical preparation.
The specific embodiment:
1. experimental technique
1.1 laboratory animal and raising condition
Three 70 of monthly age regular grade Sprangue-Dawley (SD) female rats (Guangdong Medical College's Experimental Animal Center provides), body weight 225 ± 12g.The raising condition: raise indoor temperature and keep 24 ℃ ~ 28 ℃, humidity is 50% ~ 60%.Divide cage common nursing.Two in every cage, the water of freely ingesting, specially raise the chamber, and the special messenger is responsible for, and weighs once weekly.Animal feeding and experiment three totally months.
1.2 research medicine and compound method
(1) diethylstilbestrol: Guangdong Bidi Pharmaceutical Co., Ltd; Compound method: diethylstilbestrol 2mg, distilled water 1000ml, the dissolving of heating gets final product.
(2) four vegetable oil
Refinement of evening primrose oil, refining Fructus Perillae oil, refining wheat germ oil, refining walnut oil is all purchased the dense magnificent biological engineering company limited in Dalian, and the main constituent of these several oil sees Table 1:
Table 1: the content of the main constituent of several oil
| Oils | Alpha-linolenic acid | Gamma-Linolenic acid | Linoleic acid | Vitamin E |
| Radix Oenotherae erythrosepalae oil Fructus Perillae oil wheat germ oil | - 83.84％ - | 9.2％ - - | 74.1％ 8.2％ 60％ | 0.093mg/g - 0.677mg/g |
| Walnut oil | 13.4％ | 62.2％ | - | |
1.3. experimental technique
Set up the senile osteoporosis of estrogen deficiency and the rat animal model of skin aging with the oophorectomize method, control rats adopts the sham-operation method, perform an operation equally when promptly testing, but spay not, as experiment contrast.Experiment grouping administration situation sees Table 1:
Table 1: grouping of medicine osteoporosis research experiment and administration situation
| Group | The example number | Medication | Dosage regimen |
| Sham-operation group oophorectomize group diethylstilbestrol group evening primrose oil group Fructus Perillae oil group wheat germ oil group walnut oil group | 10 10 10 10 10 10 10 | Oral filling hello oral filling is fed oral filling hello oral filling hello oral filling hello oral filling hello oral filling and is fed | Normal saline 5ml*kg -1d -1Normal saline 5ml*kg -1d -1Diethylstilbestrol 10ug*kg -1d -1Radix Oenotherae erythrosepalae oil 5ml*kg -1d -1Fructus Perillae oil 5ml*kg -1d -1Wheat germ oil 5ml*kg -1d -1Walnut oil 5ml*kg -1d -1 |
1.4. castration of animal and administration
The castration of animal: except that the sham operated rats rat, surplusly respectively organize rat and anaesthetize (0.12ml/kg) with 3% pentobarbital, under the strict sterilization condition, the operation of row ovariectomized rats was taken out stitches after one week.The sham operated rats rat is opened the abdominal cavity in same area (both sides abdominal part) and is not extractd ovary and sew up immediately.
Administration: sham operated rats and oophorectomize group per os every day are irritated and are fed normal saline 5ml*kg-1*d-1, and diethylstilbestrol group per os every day is irritated and fed diethylstilbestrol 10ug kg-1*d-1; Radix Oenotherae erythrosepalae line of oils, Fructus Perillae oil group, wheat germ line of oils, Semen Juglandis line of oils per os every day are irritated respectively and are fed Radix Oenotherae erythrosepalae oil, Fructus Perillae oil, wheat germ oil, walnut oil 5ml*kg-1*d-1.Successive administration three months.
1.5. draw materials
Behind the successive administration three months, under the anesthesia of 3% pentobarbital, rat is put to death in the right ventricle blood drawing, and separation of serum is made serum Ca and measured.Get the left side ulna, Ex-all muscle and soft tissue, 80 ℃ of baking 48h get key weight to constant weight, then in 6molL
-1HCl, digestion 16h after-filtration is got filtrate under 108 ℃ of temperature, measure calcium (Ca), phosphorus (P) content in the bone with ICP (inductance coupled plasma direct-reading spectrometer), and bone hydroxyproline (Hyp) content (the hydroxyproline test kit is that bio-engineering corporation's product is built up in Nanjing).Separate the right side tibia, open pulp cavity as sagittal, put into 10% formalin buffer and fix with sawing at near-end at a slow speed, dehydration then, plastic embedding is done in defat.Downcut undecalcified 4 μ m and 8 μ m section respectively with sclerous tissues's microtome, 4 μ m section Goldner ' s Trichrome dyeing mounting carries out bone meterological static parameter (static parameters) and measures.The 8 μ m section mounting that do not dye carries out bone meterological dynamic parameter (dynamic parameters) as Fluirescence observation and measures.
2. experimental result
The result of bone meterological static parameter as seen, the removal ovary rat is compared with control rats, the bone amount is obviously lost after 90 days, the bone trabecula number reduces (P＜0.01), the bone trabecula separating degree increases (P＜0.01), the osteoclast number increases (P＜0.01).Diethylstilbestrol makes bone amount of removal ovary rat and bone trabecula number obviously increase (P＜0.01), bone trabecula separating degree and osteoclast number obviously to reduce.Radix Oenotherae erythrosepalae oil, Fructus Perillae oil, wheat germ oil, walnut oil all can make the bone amount of removal ovary rat that increase (P＜0.05) is arranged, but with diethylstilbestrol group indifference.
The result of bone meterological dynamic parameter as seen, the ovariectomized group rat bone forms index and obviously increases: the mineralising deposition increases (P＜0.05), bone formation rate BFR/BV increases (P＜0.05).Diethylstilbestrol can suppress the bone formation rate (BFR/BV, P＜0.05) of removal ovary rat.Radix Oenotherae erythrosepalae oil, Fructus Perillae oil, wheat germ oil, walnut oil all form index to the removal ovary rat bone does not have obvious influence.
More than studies show that, walnut oil, Radix Oenotherae erythrosepalae oil, Fructus Perillae oil, wheat germ oil has tangible preventive and therapeutic effect to the experimental animal models osteoporosis.
Claims (1)
1, walnut oil is used for the application of the pharmaceutical preparation of protect against osteoporosis in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610110552 CN1927260A (en) | 2005-06-08 | 2005-06-08 | Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610110552 CN1927260A (en) | 2005-06-08 | 2005-06-08 | Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100782635A Division CN1302787C (en) | 2005-06-08 | 2005-06-08 | Use of several plant oils in medicinal formulation for preventing and treating osteoporosis and skin senility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1927260A true CN1927260A (en) | 2007-03-14 |
Family
ID=37857490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610110552 Pending CN1927260A (en) | 2005-06-08 | 2005-06-08 | Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1927260A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565930A (en) * | 2013-11-06 | 2014-02-12 | 苏州冉新生物技术有限公司 | Granule for increasing bone density |
| CN103599524A (en) * | 2013-11-07 | 2014-02-26 | 苏州冉新生物技术有限公司 | Compound walnut powder solid preparation |
-
2005
- 2005-06-08 CN CN 200610110552 patent/CN1927260A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565930A (en) * | 2013-11-06 | 2014-02-12 | 苏州冉新生物技术有限公司 | Granule for increasing bone density |
| CN103599524A (en) * | 2013-11-07 | 2014-02-26 | 苏州冉新生物技术有限公司 | Compound walnut powder solid preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1927260A (en) | Application of walnut oil in pharmaceutical preparation for preventing and treating osteoporosis | |
| CN101530508A (en) | Traditional Chinese medicine for treating ovarian cancer | |
| CN1879709A (en) | Chinese medicine for treating piles and anal fistula | |
| CN111437358A (en) | Traditional Chinese medicine composition for treating atherosclerosis caused by phlegm-turbidity and blood stasis | |
| CN1401365A (en) | Chinese health medicine | |
| CN1923265B (en) | Application of wheat germ oil in pharmaceutical preparation for preventing and treating osteoporosis | |
| CN104257762A (en) | Drug combination and purpose for preventing and curing osteoporosis | |
| CN106880756A (en) | For hypokinetic Chinese medicine composition of therapeutic and preparation method thereof | |
| CN1322871C (en) | Preparation of compound pseudo-ginseng drop pellets for treating traumatologic disease | |
| CN102742828A (en) | Dietetic therapy product for protecting prostate and preparation method thereof | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| CN101249236B (en) | Chinese and western medicine combined preparations for curing epileptic | |
| CN101912497B (en) | Medicament for treating bone fracture | |
| CN1078472C (en) | Application of theachrome in preparing medicine for plateau erythrocytosis | |
| CN104922488B (en) | A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application | |
| CN114377063B (en) | Traditional Chinese medicine composition for treating delayed fracture healing | |
| CN102327304A (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN102727710B (en) | Medicine for treating aplastic anemia | |
| CN101843705B (en) | Chinese medicament for treating lupus erythematosus | |
| CN1895314A (en) | Sanchi total saponin free-dried powdery injection against smash and its preparation | |
| CN105311341A (en) | Traditional Chinese medicine preparation for oral administration in synchronous treatment and prevention of 'four highs' | |
| CN105343493B (en) | A kind of cough-relieving benefit phlegm oral solution and preparation method thereof | |
| CN103301261A (en) | Medicine for treating transplant kidney main renal venous stenosis | |
| CN1305492C (en) | Leukemia treating Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070314 |